Charles S. Berkman Sells 25,489 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 25,489 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the transaction, the insider now directly owns 343,190 shares in the company, valued at $1,111,935.60. This trade represents a 6.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

OmniAb Price Performance

OABI stock opened at $3.20 on Thursday. OmniAb, Inc. has a one year low of $3.16 and a one year high of $6.55. The stock has a market cap of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10. The company has a fifty day moving average price of $3.68 and a two-hundred day moving average price of $4.06.

Institutional Trading of OmniAb

Hedge funds have recently modified their holdings of the stock. Palumbo Wealth Management LLC raised its holdings in OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares during the period. Sei Investments Co. increased its position in OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after buying an additional 2,888 shares during the period. SG Americas Securities LLC lifted its holdings in shares of OmniAb by 16.5% during the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock worth $144,000 after buying an additional 5,751 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after acquiring an additional 8,909 shares during the period. Finally, Woodstock Corp grew its stake in shares of OmniAb by 1.2% in the fourth quarter. Woodstock Corp now owns 802,578 shares of the company’s stock valued at $2,841,000 after acquiring an additional 9,725 shares in the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on OABI. Benchmark reiterated a “buy” rating and issued a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.